Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
03 Setembro 2024 - 5:01PM
Business Wire
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for endocrine and neurological disorders with
significant unmet medical need, today announced that Javier
Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at
the H.C. Wainwright 26th Annual Global Investment Conference on
September 10, 2024, at 4:30 p.m. ET.
Interested parties can access the live webcast here. An archived
copy of the webcast will be available on the events section of the
company’s investor relations website for approximately 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for
endocrine and neurological disorders with significant unmet medical
need. Spruce is developing its product candidate, tildacerfont, an
oral, second-generation CRF1 receptor antagonist, for the treatment
of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome
(PCOS) and major depressive disorder (MDD). To learn more, visit
www.sprucebio.com and follow us on X, LinkedIn, Facebook and
YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903641742/en/
Media Katie Beach Oltsik Inizio Evoke Comms (937)
232-4889 Katherine.Beach@inizioevoke.com media@sprucebio.com
Investors Samir Gharib President and CFO Spruce
Biosciences, Inc. investors@sprucebio.com
Spruce Biosciences (NASDAQ:SPRB)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Spruce Biosciences (NASDAQ:SPRB)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
